Health Trials

Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

ConditionsAnn Arbor Stage II Follicular LymphomaAnn Arbor Stage II Marginal Zone LymphomaAnn Arbor Stage III Follicular LymphomaAnn Arbor Stage III Marginal Zone LymphomaAnn Arbor Stage IV Follicular LymphomaAnn Arbor Stage IV Marginal Zone LymphomaGrade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular Lymphoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Washington

About this trial

This phase II trial tests the safety, side effects and effectiveness of mosunetuzumab in treating patients with slow growing (indolent) B-cell lymphoma. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.

Eligibility criteria

Qualifiers

18 years or older at time of signing informed consent

Capable of understanding and providing written informed consent

Follicular lymphoma (grade 1-2 or 3A)

Marginal zone lymphoma

Disqualifiers

History of severe allergic reaction to monoclonal antibody therapy

History of a second primary malignancy that could affect compliance with the protocol or interpretation of results except with permission of the principal investigator. Malignancies treated curatively or at low-risk of progressing at the judgment of the principal investigator (PI) may be included

Known active and uncontrolled bacterial, viral, fungal, mycobacterial, or other infection at study enrollment

Infection with human immunodeficiency virus (unless viral load is undetectable and CD4 count ≥ 200)

Trial design

Treatments tested in this trial

  • Biospecimen Collection
  • Computed Tomography
  • Magnetic Resonance Imaging
  • Mosunetuzumab
  • Positron Emission Tomography
  • Questionnaire Administration

Treatment groups

20 Participants
are divided into 1 treatment group

Sponsors and collaborators

University of Washington

Lead sponsor

Source ClinicalTrials.gov